ATLAS trial investigator Guy Young, MD, Children's Hospital Los Angeles and University of Southern California Keck School of ...

New research from the Children’s Hospital of Philadelphia shows the challenges of getting families to accept a promising new drug that protects against RSV, a common cold-like virus that can cause ...

There is a test that is usually carried out to find out whether a child has tuberculosis or not, namely the Mantoux test. The ...

A once-weekly growth hormone therapy improved growth-related endpoints for adolescents with multiple conditions of short ...

OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has ...

"We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients.

To report the results of the multicenter, open-label IRAKLIA trial (ClinicalTrials.gov identifier: NCT05405166) of isatuximab subcutaneous (SC) versus intravenous (IV), plus pomalidomide and ...

Enable Injections Presents Survey Results Highlighting Missed Opportunities in Subcutaneous Oncology Drug Development at AACR 2025 Provided by GlobeNewswire Apr 25, 2025, 10:00:00 AM ...

The average number of days missed also decreased in the group that received the subcutaneous version. Scientists have also recorded improvements in mental and emotional health and academic performance ...

A subcutaneous injectable form of nivolumab is available to treat melanoma, non-small cell lung cancer, renal cell cancer, and many other cancers.

Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist ...

Subcutaneous immunotherapy injections for cancer treatment work the same way as intravenous infusions and are just as effective.